CannaboTech Overview
Cannabotech develops advanced medical solutions for cancer, inflammation, and chronic pain. Its drug formulation method utilizes pure clinical, botanical qualities with the aim of creating an effective cure for these long-term illnesses. The company uses traditional botanical resources that have proven both therapeutic and safe in order to accelerate medicinal development and swiftly reach mainstream consumers who are looking for innovative and certified medical solutions. Cannabotech harnessed the benefits of cannabinoids and medicinal mushrooms and has created its proprietary and patent-pending formula: M²CBD. Cannabotech focuses on three classes of medical solutions: integrative care, preventive medicine, and botanical drugs.
Cumulative Funding Raised Over Time ($)
$4.0MDec 2020
$4.2MJan 2019
$6.0MOct 2019
Latest News
growth-negative
אחרי שגייסה 30 מיליון שקל מהציבור — קנבוטק בדרך להסדר נושים
Cannabotech, a public company since 2021, is currently negotiating a creditor arrangement due to severe financial distress. Initially, the company raised 30 million shekels through the crowdfunding platform Fundit, achieving a valuation of 130 million shekels. However, its valuation has since plummeted to around 10 million shekels. Cannabotech is unable to publish its mid-year financial reports because it lacks the funds to pay its auditors. The company did not go public through a traditional IPO involving institutional investors but rather through a public crowdfunding campaign.
Public TradingInvestment
growth-positive
קנבוטק כובשת את בריטניה: עסקת הענק של חברת הסטארט-אפ הישראלית
Biotechnology company Canbotec has announced a partnership with Phoenix Retail Holdings to establish a joint venture in the UK. Canbotec will provide exclusive rights to its intellectual property and permission to sell its products in physical retail stores to be established in the UK. Phoenix Retail Holdings will invest £50,000 in the project and seek additional investors in the UK. The company plans to immediately open at least three sales points in central London and about ten sales points by the end of 2025.
PartnersInvestmentExpand
growth-positive
קנבוטק חותמת הסכם במסגרתו יוקמו 3 חנויות קונספט של מותג רפואת המניעה שלה בתאילנד
Kanabo, a biotechnology company specializing in the development of a prevention medicine concept based on CBD and medicinal mushroom extracts, has signed an agreement to establish a joint venture in Thailand. As part of the agreement, Kanabo will provide the project with exclusive rights to use its intellectual property and rights for local production and sale of its prevention medicine products in branded concept stores in leading malls and on a dedicated website. MyCannabiz Global will invest at least $1 million in the project to build Kanabos brand and introduce it to the growing CBD market in Thailand.
PartnersInvestment
growth-positive
"קנבוטק" חושפת: זה ההישג החדש של חברת הסטארט-אפ הישראלית
Israeli start-up company, קנבוטק, has announced the commencement of sales in four new concept stores in the field of preventive medicine. These stores were established as part of a collaboration with Super-Pharm, which was signed in April 2022. The stores were established in a Shop-in-Shop model in Super-Pharms main branches in Warsaw, Krakow, Poznan, and Wroclaw. The company claims that each of the four new Super-Pharm stores, and the online sales on its website, will quickly reach revenues similar to those of the concept store that קנבוטק established in London.
CustomersPartnersExpand
growth-positive
כפיר אברהם מצטרף לדירקטוריון חברת קנבוטק
קנבוטק, a company involved in the development and marketing of concepts in preventive medicine and oncology, has announced that Mr. Kfir Avraham has joined the companys board of directors after leading an investment round of about 1.5 million NIS from 3 different investors. The investors received 184,050 shares at a price of 8.15 NIS per share, and an additional 368,100 options at varying exercise prices from 10.19 NIS to 25 NIS per share. The potential additional investment through the exercise of all options stands at 6.2 million NIS.
InvestmentManagement Changes
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $29M |
| Last funding | $23M |
| Stage | Public |
| Rounds | 4 |
| Investors | 3 |
Team Members
5
Employees: 1-10
Web & Social Links
| Website | cannabotech.com |
Locations
Arik Ainstain Street 3, Herzliya, Israel
Photos & Videos
2 item(s)
CannaboTech Business
Business models
B2B, B2C
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical CannabisTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatientsCore Technology
BiologicalsHerbalsTags (20)
therapeuticstopical-treatmentpersonalizationmobile-applicationscardiologysupplementsmonitoringcannabiswellnessalert-systembiotechnologybiopharmaceuticalmedical-productscancerdrug-deliverymedical-cannabispharmaceuticalsskin-carecosmeticsnutritionGeographic Markets
Southeast AsiaNorth AmericaEuropeCannaboTech Financials
$29M
Total funding
Undisclosed
Capital raised
$23M
Last funding
Public
Funding stage
4
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$4.0MDec 2020
$4.2MJan 2019
$6.0MOct 2019
Private Equity Funding
Equity crowdfunding
Dec 2020
$4M
Fundit, B WORLD CLASS
Seed
Oct 2019
$1.8M
Fundit
Pre-Seed
Jan 2019
$200K
Undisclosed Investor(s)
Public Offering / Exit
POEvent
Jul 2021
Undisclosed
CannaboTech Lifecycle
Cumulative Funding Raised Over Time
$4.0MDec 2020
$4.2MJan 2019
$6.0MOct 2019
All Events
Equity crowdfunding
Dec 2020
$4M
Fundit, B WORLD CLASS
Seed
Oct 2019
$1.8M
Fundit
Pre-Seed
Jan 2019
$200K
Undisclosed Investor(s)
POEvent
Jul 2021
Undisclosed
CannaboTech News
23 articles
growth-negative
אחרי שגייסה 30 מיליון שקל מהציבור — קנבוטק בדרך להסדר נושים
Cannabotech, a public company since 2021, is currently negotiating a creditor arrangement due to severe financial distress. Initially, the company raised 30 million shekels through the crowdfunding platform Fundit, achieving a valuation of 130 million shekels. However, its valuation has since plummeted to around 10 million shekels. Cannabotech is unable to publish its mid-year financial reports because it lacks the funds to pay its auditors. The company did not go public through a traditional IPO involving institutional investors but rather through a public crowdfunding campaign.
Public TradingInvestment
growth-positive
קנבוטק כובשת את בריטניה: עסקת הענק של חברת הסטארט-אפ הישראלית
Biotechnology company Canbotec has announced a partnership with Phoenix Retail Holdings to establish a joint venture in the UK. Canbotec will provide exclusive rights to its intellectual property and permission to sell its products in physical retail stores to be established in the UK. Phoenix Retail Holdings will invest £50,000 in the project and seek additional investors in the UK. The company plans to immediately open at least three sales points in central London and about ten sales points by the end of 2025.
PartnersInvestmentExpand
growth-positive
קנבוטק חותמת הסכם במסגרתו יוקמו 3 חנויות קונספט של מותג רפואת המניעה שלה בתאילנד
Kanabo, a biotechnology company specializing in the development of a prevention medicine concept based on CBD and medicinal mushroom extracts, has signed an agreement to establish a joint venture in Thailand. As part of the agreement, Kanabo will provide the project with exclusive rights to use its intellectual property and rights for local production and sale of its prevention medicine products in branded concept stores in leading malls and on a dedicated website. MyCannabiz Global will invest at least $1 million in the project to build Kanabos brand and introduce it to the growing CBD market in Thailand.
PartnersInvestment
growth-positive
"קנבוטק" חושפת: זה ההישג החדש של חברת הסטארט-אפ הישראלית
Israeli start-up company, קנבוטק, has announced the commencement of sales in four new concept stores in the field of preventive medicine. These stores were established as part of a collaboration with Super-Pharm, which was signed in April 2022. The stores were established in a Shop-in-Shop model in Super-Pharms main branches in Warsaw, Krakow, Poznan, and Wroclaw. The company claims that each of the four new Super-Pharm stores, and the online sales on its website, will quickly reach revenues similar to those of the concept store that קנבוטק established in London.
CustomersPartnersExpand
growth-positive
כפיר אברהם מצטרף לדירקטוריון חברת קנבוטק
קנבוטק, a company involved in the development and marketing of concepts in preventive medicine and oncology, has announced that Mr. Kfir Avraham has joined the companys board of directors after leading an investment round of about 1.5 million NIS from 3 different investors. The investors received 184,050 shares at a price of 8.15 NIS per share, and an additional 368,100 options at varying exercise prices from 10.19 NIS to 25 NIS per share. The potential additional investment through the exercise of all options stands at 6.2 million NIS.
InvestmentManagement Changes
growth-positive
קנבוטק מסמנת יעדים: "2023 היא שנת הפריצה"
Israeli company Kanabo, led by Alon Shaked, has recently signed significant agreements that may provide it with the fuel for a breakthrough. The company has successfully completed two preclinical trials to prove the safety of its botanical drug. Kanabo has also signed cooperation agreements with two Israeli companies operating abroad to break into additional markets. One agreement is with Super Pharm for a joint breakthrough in the Polish market. The second is with cannabis giant BOL Pharma to penetrate the American market in the field of preventive medicine and later in integrative oncology. BOL Pharma has agreed to invest $1 million in marketing Kanabos products in the US.
InvestmentPartnersExpand
growth-positive
קנבוטק צלחה שני ניסויים פרה-קליניים לבטיחות תרופה לסרטן
Israeli company קנבוטק has successfully completed two pre-clinical trials for its botanical drug developed for the treatment of gastric and colorectal cancer. The trials were conducted in the laboratory of Prof. Fuad Fares at the University of Haifa. The companys stock has risen by about 24% on the Tel Aviv Stock Exchange, completing a sharp rise of about 69% over the past week. The success of the trials is a significant step in the development of the drug, a process expected to be completed in the coming months. The company plans to collaborate with a strategic partner from big-pharma companies and will work for approval from the FDA.
InvestmentPartners
growth-positive
Over 90% report improvement in psoriasis, says Cannabotech
Cannabotech, a biomedical company that develops preventative solutions using CBD and functional mushrooms, has reported positive results from a study of its Nurture products in treating psoriasis. The study, conducted by Ayton Global Research, tested the products on 120 volunteers diagnosed with psoriasis. The Nurture products combine pharmaceutical-grade CBD with a blend of functional mushrooms to promote healthy skin functioning. According to the company, over 90% of respondents reported improvements in their skins appearance and reduced psoriasis symptoms.
Customers
growth-positive
Promising Breakthrough in Cannabotech's Pancreatic Cancer Drug: For the first time ever, the botanical drug has shown a combined anti-cancer effect between cannabis and mushroom
Cannabotech, an Israeli BioMed company, is developing a botanical drug based on Cyathus striatus fungal extract and cannabinoids extracts from the cannabis plant. The drug has shown promising results in killing pancreatic cancer cells with high efficacy. The company expects to complete the feasibility and safety test phase by mid-2023. The drug development process is being led by Prof. Fuad Fares, a senior cancer researcher at the University of Haifa. The company plans to commence marketing toward the end of 2022 in California and later, also in Israel, in early 2023.
InvestmentExpand
growth-positive
Cannabotech's botanical drug for pancreatic cancer has demonstrated killing 100% of cancer cells without damaging the healthy cells in the cell model
Cannabotech, an Israeli biomed startup, is developing a botanical drug based on an extract of the Cyathus striatus fungus and a cannabinoid extract from the cannabis plant for the treatment of pancreatic and colon cancer. The drug has shown promising results in cell model trials, eliminating 100% of pancreatic cancer cells without damaging normal cells. The company expects to complete the feasibility and safety testing phase by mid-2023 and then seek a development collaboration with a large pharma company. Cannabotech is also developing a series of 9 preparations to aid in anti-cancer treatment and the side effects of chemotherapy.
InvestmentExpand
growth-positive
Cannabotech partners with go NXT LVL to manufacture oncology products in California
Israeli biomedical startup Cannabotech has announced a strategic partnership with Californian corporation go NXT LVL. The partnership will allow Cannabotechs integrative oncology products to be developed and manufactured at go NXT LVLs facilities in accordance with the California Medical Cannabis Regulations. Sales of its products to oncologists and integrative caregivers are expected to start in Q4 of 2022 in California. In addition, Cannabotech plans to leverage go NXT LVLs distribution network as part of its California market penetration strategy. Following the launch of their products in California, Cannabotech also hopes to bring their products to market in the UK and Israel.
PartnersExpand
growth-positive
Mixing medical mushrooms and cannabis for cancer care
Herzliya-based startup Cannabotech is developing a treatment that combines cannabis and medical mushrooms to potentially reduce the amount of chemotherapy needed by cancer patients. The treatment has shown promising results in lab studies, increasing the mortality of cancer cells from 10 to 60 percent. Cannabotech is targeting five types of cancer initially: breast, pancreatic, colon, lung, and prostate. The company has raised $13.4 million and is publicly traded on the Tel Aviv Stock Exchange. It employs 12 people in Israel and another 10 in the UK.
CustomersInvestmentExpand
growth-positive
Cannabotechs "Integrative-Colon" products eliminated over 90% of colon cancer cells in a cell model experiment
Cannabotech, an Israeli biomedical company, has reported that its Integrative-Colon products, based on cannabis and mushroom extracts, killed over 90% of colon cancer cells in a cell model study. The study also highlighted the need for personalised medical care, a technology that Cannabotech is currently developing. The products are expected to hit the market in Israel, the US, and the UK towards the end of 2022. The companys CEO, Elhanan Shaked, stated that this is a significant milestone in Cannabotechs growth to becoming a leader in integrative oncology medicine.
CustomersExpand
growth-positive
Cannabotech's IntegrativePain products show an 80%-100% reduction in inflammatory pain
Cannabotech, an Israeli biomedical company, has reported positive results from a study using mushroom compounds in conjunction with cannabinoids to achieve an 80%-100% reduction in pain sensation. The treatment is expected to be launched in Israel, US and UK in the second half of 2022 and be incorporated as part of Cannabotechs Integrative Oncology solutions concept. The company is also developing three pain-treatment formulas for different types of pain and a personalization system to provide physicians with the information to help them make informed and customized decisions using IntegrativePain products.
Expand
growth-positive
Research shows CannaboBreast products have sixfold improvement in killing cancer cells
Cannabotech, an Israel-based biomedical company, has conducted a study showing that its product, CannaboBreast, when used in conjunction with standard chemotherapy, can be up to six times more effective in killing cancer cells. The study also revealed that CannaboBreast could allow for decreased doses of chemotherapy, thus reducing side effects. The product is based on a unique combination of cannabinoids, terpenes from the cannabis plant, and functional mushrooms extracts. The treatment is expected to be commercialized in the second half of 2022 and be integrated as part of Cannabotechs integrative solutions concept.
CustomersExpand
growth-positive
Israel's Cannabotech Working On New Treatment For Pancreatic And Colon Cancer Combining Cannabis & Fungus - Benzinga
Israeli biotech company Cannabotech has acquired exclusive rights to a patent for developing plant-based cancer treatments. The company is working on a drug to kill cancer cells in patients with pancreatic and colon cancer. This follows a study by Hadassah Medical Center physicians that found a six-fold improvement in killing breast cancer cells when using specific Cannabotechs medical cannabis products in combination with standard oncology treatments. Cannabotech and Haifa Universitys economic company Carmel have entered a deal to develop combined products that could advance cancer treatments.
PartnersInvestment
growth-positive
חברת הקנאביס קנבוטק תיסחר בת"א: "ביצענו את גיוס ההמונים הגדול בישראל" כלכליסט
Cannabis company Cannabotech has raised 26.6 million shekels through a crowdfunding campaign on the Fundit platform, based on a valuation of 134 million shekels. The company, which develops medical cannabis-based products and botanical medicine for cancer, will now be publicly traded on the Tel Aviv Stock Exchange. Cannabotech operates in three main areas: CBD-based health products and medicinal mushrooms sold in the UK and European market, medical cannabis-based products and mushroom-based dietary supplements for various medical symptoms including different types of cancer, inflammation and chronic pain, and the development of botanical drugs.
InvestmentPublic Trading
growth-positive
מנכ"ל קנבוטק: "מטרת החברה להיות מובילה עולמית של רפואה מניעתית ואינטגרטיבית"
Herzliya-based bio-medical company, Kanbotek, which specializes in the research and development of cannabis-based medical products, is planning to go public. The company is aiming for a company value of around 134 million NIS and will register on the Tel Aviv Stock Exchange. Kanbotek was founded in early 2019 and has since developed 35 different products. The company is planning to expand to other countries in Europe by the end of 2021 and in the US during 2022.
InvestmentPublic Trading
growth-positive
קנבוטק: החברה הישראלית שמתכוונת לכבוש את בריטניה עם קנאביס ופטריות
Israeli company Canbotec is launching a digital campaign in England to announce the arrival of its products in the UK market. This is the first step in the companys planned expansion into the European market. Canbotec has developed 35 products based on a combination of the cannabinoid CBD and active ingredients derived from medicinal mushrooms. The company plans to sell its products in England through a virtual store and a special concept store expected to open later this year in central London. Canbotec is currently raising funds from the public through an IPO on the digital investment platform Fundit.
ExpandInvestment
growth-positive
Cannabotech wants to raise $6 million in Israel's first crowdfunded share issuance
Cannabotech, a developer of medical solutions based on botanical combinations of cannabis extracts and fungi, is planning to raise nearly $6 million through a direct share issuance to the public. The company plans to become a public, non-traded startup, a model that has not yet been implemented in Israel. The shares will be listed on the Tel Aviv Stock Exchange (TASE) in the future. The issuance will be performed digitally and directly to the public on the digital platform of Fundit, a Poalim IBI company.
InvestmentPublic Trading
cbdhealthcures.com
The article content is not available as the page could not be found. Readers are directed to the main page.
growth-positive
SC-FI or Medicine: Combining Psychedelics and Marijuana - Leader Bulletin
Israeli medical cannabis firm Cannabotech is researching combinations of cannabinoids, medicinal herbs, and mushrooms to treat a variety of medical conditions. The company has developed five unique blends designed to treat colon cancer, infertility, fatty liver, inflammation, and heart or vascular disease. These mixtures are now awaiting clinical trials. Cannabotech is currently working with non-psychedelic mushrooms, but the growing body of research suggesting that psilocybin can be as effective as medical marijuana could influence future developments.
CustomersInvestmentExpand
growth-positive
Cannabotech combines cannabis with mushrooms
Israeli company Cannabotech is developing unique medicinal products that combine cannabis with other medicinal herbs, including mushrooms. The company has developed five such products to date for treatment of colon cancer, unexplained infertility, fatty liver, reduction of inflammatory activity, and heart and vascular diseases. These products are awaiting clinical trials. Cannabotech recently embarked on a crowdfunding project. CEO Elchanan Shaked believes in building the company from below, without direction from capital market people.
CustomersInvestment
CannaboTech Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 10 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
CannaboTech Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yotam Maman |
| Registrar ID | 515949337 |
| Crunchbase | cannabotech |
| Phone | +97233752732 |
| Creator | Yoav Rothler |
| Creator email | yoav@cannabotech.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-12-07T00:00:00.000Z |
| Created | 2019-04-04T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on TASE on Jul, 2021; |